Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Surg Res. 2020 Feb;246:207-212. doi: 10.1016/j.jss.2019.08.016. Epub 2019 Oct 9.
The use of left ventricular assist devices (LVADs) as a bridge to heart transplantation has increased rapidly over the last 2 decades. We aim to explore the effect of pretransplant systemic and device-related complications on posttransplant survival for patients bridged with LVADs.
The United Network of Organ Sharing (Organ Procurement and Transplantation Network) database was queried for all adult heart transplant recipients (aged ≥ 18 y) transplanted from April 1, 2015, to June 31, 2018. Device-related complications included thrombosis, device infection, device malfunction, life-threatening arrhythmia, and other device complications. Systemic complications included a new dialysis need or ventilator dependence between the time of listing and transplantation, transfusion, or systemic infection requiring treatment with intravenous antibiotics within 2 wk of transplantation.
A total of 2131 patients were identified as requiring LVAD support before transplantation. LVAD patients had high rates of preoperative systemic complications (53%) and high rates of device-related complications (42.7% experienced at least one device-related complication). Kaplan-Meier analysis revealed a significantly decreased 1-y survival for LVAD patients bridged to transplantation who experienced a pretransplant systemic complication (P = 0.041). Interestingly, preoperative device-related complications had no effect on 1-y posttransplantation survival (P = 0.93). Multivariate Cox modeling revealed that systemic complications were associated with a significantly increased risk of posttransplant mortality for LVAD patients (hazard ratio 1.45; P = 0.033).
Recipients who suffered a systemic complication while awaiting heart transplantation experienced higher short-term mortality rates. Device-related complications do not appear to impact posttransplantation outcomes.
在过去的 20 年中,使用左心室辅助装置(LVAD)作为心脏移植的桥接手段迅速增加。我们旨在探讨在 LVAD 桥接患者中,移植前全身和与器械相关的并发症对移植后生存的影响。
检索 2015 年 4 月 1 日至 2018 年 6 月 31 日期间所有接受成人心脏移植(年龄≥18 岁)的 United Network of Organ Sharing(器官获取和移植网络)数据库。器械相关并发症包括血栓形成、器械感染、器械故障、危及生命的心律失常和其他器械并发症。全身并发症包括在列入名单和移植之间需要新的透析或呼吸机依赖、输血或移植后 2 周内需要静脉用抗生素治疗的全身感染。
共确定 2131 例患者在移植前需要 LVAD 支持。LVAD 患者术前全身并发症发生率高(53%),器械相关并发症发生率高(42.7%至少经历过一次器械相关并发症)。Kaplan-Meier 分析显示,移植前发生全身并发症的 LVAD 患者 1 年生存率显著降低(P=0.041)。有趣的是,术前器械相关并发症对移植后 1 年生存率没有影响(P=0.93)。多变量 Cox 模型显示,全身并发症与 LVAD 患者移植后死亡风险显著增加相关(危险比 1.45;P=0.033)。
在等待心脏移植期间发生全身并发症的患者短期死亡率较高。器械相关并发症似乎不会影响移植后的结果。